NKTX - Why Is Cancer Drug-Developer Nkarta Stock Trading Lower On Friday? | Benzinga
Thursday, in its fourth quarter 2023 earnings release, Nkarta Inc (NASDAQ:NKTX) said it closed patient enrollment in its clinical trial of NKX101 and deprioritized the program as part of a pipeline realignment that directs primary resources to its lead pipeline program, NKX019, for autoimmune disease.
This follows a recent review of preliminary safety and response data from patients with r/r AML who received NKX101 after lymphodepletion (LD) comprising fludarabine and cytarabine (flu/Ara-C).
The aggregate CR/CRi rate (5 of 20 patients) was lower than observed in the first six patients ...